Fig. 2: Upregulation of CXorf56 protein correlates with a poor prognosis for human BC.
From: Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
A Representative IHC images of CXorf56 protein expression (nuclear staining pattern) in non-TNBC tissues and TNBC tissues; Scale bar = 50 μm. The scores indicate CXorf56 protein levels in tumor tissues in different subgroups (B, non-TNBC vs. TNBC; C, stage I-II vs. stage III; D, tumor size <3 cm vs. tumor size >3 cm). The scores were calculated by the intensity and percentage of stained cells as described in the methods. Data were analyzed by a two-tailed t test. E BC patients with high CXorf56 protein expression (score of 4–7) have poorer OS than patients with low CXorf56 protein expression (score of 0–3). Data were analyzed by a log-rank test. F The expression of CXorf56 protein is an independent prognostic factor for OS of BC patients, based on the multivariate Cox proportional hazard model, which is shown in the forest plot. Data were analyzed by a Wald test. Remarks: nsp ≥ 0.05, ***p < 0.001, ****P < 0.0001.
